Bronwyn has over 20 years executive experience in health technology commercialisation, venture capital, capital raising and industry advocacy. In 2017 she founded ANDHealth, an organisation that supports digital health companies in Australia by providing education, resources, non-dilutive funding and mentorship to help them navigate the complexities of the healthcare industry.

ANDHealth is now one of Australia’s leading health technology commercialisation organisations with companies participating in its flagship ANDHealth+ program raising $19.70 in new capital and generating $6.70 in new revenues for every dollar invested. ANDHealth manages over $30M in public and private commitments to digital health commercialisation, and provides specialist support to a further $100M of funding managed by Brandon Capital.

Bronwyn was a member of the National Health & Medical Research Council for the 2021-2024 Triennium. She is currently a Non-Executive Director of Lumos Diagnostics Ltd (ASX.LDX) alongside a number of other advisory roles.

Liz Ashall-Payne is an accomplished healthcare leader and the Founding CEO of ORCHA, a global leader in digital health accreditation and distribution services. With a background as a trained NHS Clinician, Liz has been at the forefront of healthcare transformation programs in the NHS, Europe, and North America, leveraging the potential of digital technology to enhance patient health outcomes and drive economic opportunities.

In 2015, Liz established ORCHA, a groundbreaking venture. Under Liz's guidance, ORCHA has experienced remarkable growth, expanding its digital health assessment and distribution services to twelve countries worldwide. Within the UK, ORCHA serves organisations in 70% of NHS regions, positioning itself as a trusted partner in the digital health landscape.

Recognised for her exceptional contributions, Liz Ashall-Payne and ORCHA have received numerous accolades. Liz herself has been honoured as a Tech Trailblazer by the BIMA 100, acknowledged as a Healthcare IT Leader in the HIMSS Future 50, and named Entrepreneur of the Year by prestigious institutions such as the British Chamber of Commerce, Norther Powerhouse, and EY. Additionally, she has been featured within the LDC top 50, further highlighting her influential role in the healthcare and technology sectors.

In addition to her accomplishments at ORCHA, Liz Ashall-Payne actively contributes to the development of future healthcare leaders as a coach for the NHS England Clinical Entrepreneur program. Furthermore, Liz serves as a member of Tech Uk board representing SMES and is the Vice Chair on the Tech UK Health and Social Care Council, where she helps shape policies and initiatives in the intersection of technology and healthcare.

Liz is also an honorary lecturer in the school of medicine at UCLAN, and is a research executive at The University of Warwick

Liz Ashall-Payne's visionary leadership, extensive expertise in healthcare transformation, and dedication to harnessing the potential of digital health make her a prominent figure in the industry, driving positive change and innovation for the benefit of patients and healthcare systems worldwide.

Catherine de Fontenay commenced a 5-year term as a full time Commissioner with the Productivity Commission in July 2019.

After completing her PhD in 1998 at Stanford University, Catherine has held faculty positions at the University of New South Wales, then University of Melbourne, with a visiting position at New York University.  Her research on team sin science has been published in Nature Biotechnology.

Catherine leads the Health Productivity stream of research at the PC. She has led work on Measuring Healthcare Productivity, Digital Technologies in Healthcare, Aged Care Employment, and Unpaid Leave for Carers.

Catherine is also currently the President for the Economic Society of Australia.

Chris is a founding partner of Brandon Capital and Chief Executive Officer of Brandon BioCatalyst. Chris was previously the Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia.  Prior to this, Chris was the Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne. Concurrently he was an Investment Manager for, and on the investment committee of, Uniseed Pty Ltd. Chris has international experience working for the business development group of Leiras Pharmaceuticals in Finland, a wholly owned subsidiary of Schering AG.

Chris is currently a director of; Azura Ophthalmics, Certa Therapeutics, EBR Systems (ASX:EBR), Global Kinetics Corporation, OccuRx, PolyActiva and Que Oncology. He is also an elected board member of the Australian Investment Council, Chair of CUREator and an advisory board member for The WILD Program.

Chris has a Bachelor of Science (Honours) from The University of Melbourne and a PhD in Endocrinology and Physiology from The University of Melbourne. He studied Private Equity and Venture Capital at Harvard Business School.

Olivia holds Bachelors degrees in both Science and Engineering, specialising in molecular biology and mechatronics, alongside a Masters of Applied Cybernetics from the Australian National University.  

Olivia has extensive experience within both the TGA in the regulation of high risk medical devices, and the Digital Transformation Agency with a focus on enabling better digital services delivered by government. She is currently a director in the Medical Devices Authorisation Branch, responsible for the team that assesses the safety and efficacy of medical device software, including those incorporating AI and ML.

‍

Peter Chan is an Intensive Care Specialist at Eastern Health, Melbourne. He has recently completed a PhD in the validation of medical devices at Monash University. He is interested in the intersection of technology and patient care in the clinical space. He is currently deputy director of research at Eastern Health ICU services and sits on the Human Research and Ethics Committee. He also sits on a number of advisory boards for healthtech startups and is passionate about finding ways of bringing novel technology to the patients that might benefit from them.

A highly experienced leader in digital health service delivery, Jill is recognised in Australia and internationally for her work in transformative health technology solutions. She is passionate about improving equity and accessibility in the healthcare industry and has extensive experience in leading teams to devise sustainable health innovations.

Jill is committed to building deep connections across the health system to drive the adoption and acceleration of innovative new technologies that deliver more efficient and engaging services.

Clare is a PhD-qualified research scientist with extensive experience in project and stakeholder management and the commercialisation of academic research.

Clare has direct experience in the commercialisation of personalised medicine, bioinformatics and computational biology research projects.

Over his 35 year career Gavin has been a leader and champion of Medical Technology in Australia/NZ and Asia. He has also played lead roles in Industry Bodies, Innovation Initiatives and Not for Profit Boards. Gavin is strong advocate for Gender Equality and Indigenous Engagement.

Gavin is currently CEO of Omnigon, a private Australian company in the Ostomy Care market. He is Chair of ANDHealth (Australia’s National Digital Health Initiative), Board Director for Bowel Cancer Australia and Board Director for SAN Foundation. Gavin is a proud member of the Champions of Change Coalition Health group, sits on SBE Life Sciences Council and ARCS Signature Program Advisory Board, and serves as an Ambassador for Rotary Oceania Medical Aid for Children (ROMAC).

Previously, Gavin was Managing Director Australia/NZ and Vice President Asia Pacific for Johnson & Johnson Medical Devices, Chair of the Medical Technology Association of Australia, Governor of American Chamber of Commerce, Co-Founder/Chair of Macquarie Park Business Coalition (in partnership with United Way) and Australian Co-Chair of the Health Technology Sector Group of the Australia/NZ Leadership Forum.

Gavin is a Graduate of the Australian Institute of Company Directors.

As a co-inventor on a patented and ASX listed digital health technology; Grace Lethlean has been actively involved in the development of health technologies from invention, through clinical trials, to commercialisation.

Grace is co-founder and Chief Product Officer of ANDHealth, Australia’s national digital health initiative, accelerating the commercialisation of evidence-based digital health technologies. Grace’s focus is on supporting digital health technologies to meet key investor, partner and customer requirements around clinical and commercial validation.

Grace also supports the sector through numerous state and national Advisory Panels and Committees, is a 2020 SuperStar of STEM, is an inventor on patents in the US and Australia, a published author on digital health commercialisation, a 2022 Churchill Fellow, investigating international best practice in digital health business support and recognised in 2024 as an AFR Women in Leadership.